Advances in risk predictive performance of pre-symptomatic type 1 diabetes via the multiplex Antibody-Detection-by-Agglutination-PCR assay.
autoimmune diseases
immunology
islet autoantibodies
pediatrics
type 1 diabetes mellitus
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2024
2024
Historique:
received:
18
11
2023
accepted:
22
01
2024
medline:
23
2
2024
pubmed:
23
2
2024
entrez:
23
2
2024
Statut:
epublish
Résumé
Achieving early diagnosis of pre-symptomatic type 1 diabetes is critical to reduce potentially life-threatening diabetic ketoacidosis (DKA) at symptom onset, link patients to FDA approved therapeutics that can delay disease progression and support novel interventional drugs development. The presence of two or more islet autoantibodies in pre-symptomatic type 1 diabetes patients indicates high-risk of progression to clinical manifestation. Herein, we characterized the capability of multiplex ADAP assay to predict type 1 diabetes progression. We obtained retrospective coded sera from a cohort of 48 progressors and 44 non-progressors from the NIDDK DPT-1 study. The multiplex ADAP assay and radiobinding assays had positive predictive value (PPV)/negative predictive value (NPV) of 68%/92% and 67%/66% respectively. The improved NPV stemmed from 12 progressors tested positive for multiple islet autoantibodies by multiplex ADAP assay but not by RBA. Furthermore, 6 out of these 12 patients tested positive for multiple islet autoantibodies by RBA in subsequent sampling events with a median delay of 2.8 years compared to multiplex ADAP assay. In summary, multiplex ADAP assay could be an ideal tool for type 1 diabetes risk testing due to its sample-sparing nature (4µL), non-radioactiveness, compatibility with widely available real-time qPCR instruments and favorable risk prediction capability.
Identifiants
pubmed: 38390205
doi: 10.3389/fendo.2024.1340436
pmc: PMC10882067
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1340436Informations de copyright
Copyright © 2024 Tandel, Hinton, de Jesus Cortez, Seftel, Robinson and Tsai.
Déclaration de conflit d'intérêts
DT, BH, FJC, PR, DS, and C-tT were employed by Enable Biosciences. FJC, DT, PR, DS, and C-tT are shareholders of Enable Biosciences. PR and C-tT are inventors of the ADAP patent licensed from University of California, Berkeley to Enable Biosciences. The ADAP assay used in this study is a product in development. This does not alter our adherence to journal policies on sharing data and materials.